Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A cross-over open-label single-center study to determine whether coadministration of Viloxazine ER and Methylphenidate impacts pharmacokinetics of either drug alone

Next Previous
Trial Profile

A cross-over open-label single-center study to determine whether coadministration of Viloxazine ER and Methylphenidate impacts pharmacokinetics of either drug alone

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jan 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methylphenidate (Primary) ; Viloxazine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Sponsors Supernus Pharmaceuticals

Most Recent Events

  • 05 Jan 2021 New trial record
  • 23 Dec 2020 Primary endpoint (Relative bioavailability of viloxazine and methylphenidate, ie comparing drug plasma exposure when administered alone relative to that of combination) has been met, according to results published in the Clinical Drug Investigation
  • 23 Dec 2020 Results published in the Clinical Drug Investigation

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top